Market Closed -
Irish S.E.
11:55:00 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
5.5
EUR
|
0.00%
|
|
-1.79%
|
+22.22%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
207.7
|
188.4
|
292.4
|
246.8
|
84.63
|
103.9
|
-
|
-
|
Enterprise Value (EV)
1 |
207.7
|
216.1
|
292.4
|
72.91
|
55.33
|
75.77
|
77.04
|
78.42
|
P/E ratio
|
-
|
-
|
7.88
x
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5,951,457
x
|
4,594,589
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
5,951,457
x
|
5,270,199
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-9.65
x
|
-
|
-
|
-12.9
x
|
-25.3
x
|
-25.7
x
|
-26.1
x
|
EV / FCF
|
-
|
-63.6
x
|
-
|
-
|
-17.3
x
|
-70.5
x
|
-60.4
x
|
-57
x
|
FCF Yield
|
-
|
-1.57%
|
-
|
-
|
-5.78%
|
-1.42%
|
-1.65%
|
-1.75%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
45,750
|
45,946
|
43,635
|
33,996
|
18,806
|
18,889
|
-
|
-
|
Reference price
2 |
4.540
|
4.100
|
6.700
|
7.260
|
4.500
|
5.500
|
5.500
|
5.500
|
Announcement Date
|
-
|
3/23/21
|
3/15/22
|
2/16/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
|
34.9
|
41
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-22.4
|
-
|
-
|
-4.3
|
-3
|
-3
|
-3
|
EBIT
1 |
-
|
-22.4
|
-
|
-
|
-4.5
|
-3
|
-3
|
-3
|
Operating Margin
|
-
|
-54.63%
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
91
|
-
|
-
|
-
|
-2
|
-2.2
|
-2.3
|
Net income
|
-
|
-
|
37.8
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
0.8500
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-3.4
|
-
|
-
|
-3.2
|
-1.075
|
-1.275
|
-1.375
|
FCF margin
|
-
|
-8.29%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
-
|
3/23/21
|
3/15/22
|
2/16/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
27.7
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
174
|
29.3
|
28.1
|
26.9
|
25.5
|
Leverage (Debt/EBITDA)
|
-
|
-1.237
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-3.4
|
-
|
-
|
-3.2
|
-1.08
|
-1.28
|
-1.38
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
-
|
3/23/21
|
3/15/22
|
2/16/23
|
2/28/24
|
-
|
-
|
-
|
Average target price
11.7
EUR Spread / Average Target +112.82% Consensus |
1st Jan change
|
Capi.
|
---|
| +22.22% | 111M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|